Barely Significant
← all excerpts

An exposure-response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis.

CPT Pharmacometrics Syst Pharmacol · 2022 · PMC9574745 · PMID 36047474

Europe PMCDOI
1
hedged sentence
0.0010
closest p · 0.0× alpha
0.0010
boldest claim

The sentences

highly significantp < 0.001actually significant
Although there was no significant association between ponesimod systemic exposure (AUC ss ) or PD end points (LC ss or ΔLC ss ) and ARRs, there was a highly significant association between CUALs and ARRs, resulting in a MVOF decrease of 34.838 points (df = 1, p < 0.001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.